Performance of Second Generation Cortisol Assay Evaluated
|
By LabMedica International staff writers Posted on 21 Dec 2016 |
|
Image: The cobas e 411 fully automated, random access system for immunoassay analysis (Photo courtesy of Roche Diagnostics).
Untreated disorders of the adrenocortical system, such as Cushing’s or Addison’s disease, can be fatal, and accurate quantification of a patient’s cortisol levels is vital for diagnosis. A straightforward diagnostic approach is of essential importance, and accurate quantification of cortisol levels plays a key role in the diagnosis of patients with suspected disease.
Cortisol levels are often measured from a patient’s serum or plasma, which reflects total cortisol, both free and bound. However, in patients with liver disease, and for those receiving estrogen treatments or with critical illness, total serum cortisol levels may be difficult to interpret because of the variation in binding proteins.
Laboratory scientists at the Hospital of the University of Munich (Munich, Germany) and their colleagues performed a technical evaluation of the Elecsys Cortisol II assay (Roche Diagnostics GmbH, Mannheim, Germany) between June and November 2014 at four European investigational sites: three in Germany (Munich, Heidelberg, and Leipzig) and one in Belgium (Ghent). All sites used cobas e 411 analyzers for the Cortisol II assay experiments and in addition to a cobas e 411 system, the Leipzig site utilized a cobas e 601 analyzer. The Cortisol II assay was also compared with in-house isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays.
The team reported that for the method comparison studies, the serum samples covered a measuring range of 1.7 to 1,735 nmol/L and the saliva samples from 1.5 to 209.5 nmol/L. For the 405 serum samples, the agreement between the Cortisol II assay and LC-MS/MS was high, and the mean bias for serum samples measured on the Cortisol II assay compared with LC-MS/MS was 14.55 nmol/L. The correlation coefficient for the relationship between the Cortisol II assays versus LC-MS/MS for 253 saliva samples was 0.993, and for these comparisons, the mean bias was 2.56 nmol/L.
The authors concluded that for the Cortisol II assay, they observed a degree of between-laboratory and between-production lot reproducibility and agreement with several assays of higher metrological order that they consider compatible with the diagnostic use of this assay. The Cortisol II assay will be beneficial to endocrinologists in assessing patients with adreno-cortisol disorders. The study was published on November 29, 2016, in the journal Clinical Chemistry and Laboratory Medicine.
Related Links:
Hospital of the University of Munich
Roche Diagnostics
Cortisol levels are often measured from a patient’s serum or plasma, which reflects total cortisol, both free and bound. However, in patients with liver disease, and for those receiving estrogen treatments or with critical illness, total serum cortisol levels may be difficult to interpret because of the variation in binding proteins.
Laboratory scientists at the Hospital of the University of Munich (Munich, Germany) and their colleagues performed a technical evaluation of the Elecsys Cortisol II assay (Roche Diagnostics GmbH, Mannheim, Germany) between June and November 2014 at four European investigational sites: three in Germany (Munich, Heidelberg, and Leipzig) and one in Belgium (Ghent). All sites used cobas e 411 analyzers for the Cortisol II assay experiments and in addition to a cobas e 411 system, the Leipzig site utilized a cobas e 601 analyzer. The Cortisol II assay was also compared with in-house isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays.
The team reported that for the method comparison studies, the serum samples covered a measuring range of 1.7 to 1,735 nmol/L and the saliva samples from 1.5 to 209.5 nmol/L. For the 405 serum samples, the agreement between the Cortisol II assay and LC-MS/MS was high, and the mean bias for serum samples measured on the Cortisol II assay compared with LC-MS/MS was 14.55 nmol/L. The correlation coefficient for the relationship between the Cortisol II assays versus LC-MS/MS for 253 saliva samples was 0.993, and for these comparisons, the mean bias was 2.56 nmol/L.
The authors concluded that for the Cortisol II assay, they observed a degree of between-laboratory and between-production lot reproducibility and agreement with several assays of higher metrological order that they consider compatible with the diagnostic use of this assay. The Cortisol II assay will be beneficial to endocrinologists in assessing patients with adreno-cortisol disorders. The study was published on November 29, 2016, in the journal Clinical Chemistry and Laboratory Medicine.
Related Links:
Hospital of the University of Munich
Roche Diagnostics
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Multi-Chamber Washer-Disinfector
WD 390
Rapid Sepsis Test
SeptiCyte RAPID
Latest Immunology News
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
Channels
Molecular Diagnostics
view channel
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Pathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more
